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Editorial
Antiphospholipid syndrome
The antiphospholipid syndrome (APS) is a systemic autoim-
mune disease characterized by arterial and venous throm-
bosis, gestational morbidity and presence of elevated and 
persistently positive levels of antiphospholipid antibodies.1 
The treatment of APS is controversial, especially because 
of the absence of good quality clinical studies. In the prima-
ry prevention of thrombosis, clinical studies report different 
results.2,3 The association of risk factors with thrombotic 
events and the type and number of positive antiphospho-
lipid antibodies are current concepts and should be consi-
dered in the therapeutic decision, be it medicamentous or a 
change in lifestyle.
Full anticoagulation for undetermined time is indicated 
for secondary prevention, but the therapeutic target is still 
discussed. Although retrospective studies have suggested a 
lower number of recurrences with an elevated international 
normalized ratio (INR), prospective studies do not corrobo-
rate such fi ndings.4,5 However, the inclusion of patients with 
arterial thrombosis in those protocols was small, making the 
defi nitive conclusion about the target INR in APS diffi cult.
The obstetric questions have also generated discussion: 
teratogenicity associated with warfarin6 and the dosing of 
heparin in patients with vascular APS have little scientifi c 
evidence.7
International efforts aimed at designing and conducting 
good quality prospective studies for patients with antiphos-
pholipid antibodies, such as the creation of a multicenter 
data bank, have been observed.8 Thus, new perspectives ari-
se and, in the near future, we will have answers based on 
better evidence regarding the treatment of APS, including 
the use of hydroxychloroquine for primary prevention, the 
use of new anticoagulants, and biologic therapy. 
In face of the need to improve understanding and treat-
ment, and to establish recommendations for rheumatolo-
gists and other specialists about the management of APS, 
the Committee of Vasculopathies and APS of the Brazilian 
Society of Rheumatology (SBR), with the support of the Bra-
zilian Medical Association (AMB), publishes this guideline, 
elaborated from nine relevant and controversial clinical 
questions related to the treatment of APS, based on the best 
scientifi c evidence available. 
Once fi nished this fi rst publication, our committee pro-
ceeds to the objectives established for the next two years: 
elaboration and publication of guidelines for the diagnosis 
of APS and elaboration and publication of guidelines and 
manuals for patients with Granulomatosis with Polyangii-
tis and Takayasu’s Artheritis. In addition, the committee has 
been working along with AMB to include the following tests 
in the table of procedures: IgM/IgG anti-beta 2-glycoprotein 
I test; IgA anticardiolipin test; antiproteinase 3 test; and an-
timyeloperoxidase test.
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